Skip to main content
Fig. 7 | Arthritis Research & Therapy

Fig. 7

From: Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial

Fig. 7

Change in C1M from baseline. Values are mean ± SE. ns not significant. *Significant p = 0.0227

Back to article page
\